抗凝固薬の世界市場2018-2025

Allied Market Researchが発行した調査報告書(DATA8102145)
◆英語タイトル:Anticoagulants Market by Drug Class (NOACs, Heparin & LMWH, Vitamin K Antagonist, and Others), Route of Administration (Oral Anticoagulant and Injectable Anticoagulant), and Application (Atrial Fibrillation & Heart Attack, Stroke, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025
◆商品コード:DATA8102145
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2018年7月
◆ページ数:215
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single UserUSD5,370 ⇒換算¥601,440見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥722,400見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算¥1,007,440見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

The global anticoagulants market was valued at $24,265 million in 2017, and is expected to reach $43,427 million by 2025, growing at a CAGR of 7.5% from 2018 to 2025. Anticoagulants, commonly known as blood thinners, are chemical substances that prevent or reduce coagulation of blood and prolong the clotting time. The market has different types of anticoagulant drugs, and each drug works by inhibiting various pathways of blood coagulation. These drugs are majorly used for high risk of blood clots, such as atrial fibrillation, deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke, and others.
The global anticoagulants market is expected to grow at a significant rate during the forecast period, owing to increasing prevalence of venous thromboembolism (VTE) and cardiovascular disease across the world, growing adoption of novel oral anticoagulants (NOACs), and growing awareness of NOACs in developing regions. Furthermore, increasing obese and geriatric population and growing demand of novel therapeutics are anticipated to further influence the market growth during the forecast period. On the other side, higher price of NOACs and lack of antidots for NOACs impede the market growth.

The global anticoagulants market is segmented based on drug class, route of administration, application, and region. On the basis of drug class, the anticoagulants market is classified as NOACs, heparin & LMWH, vitamin K antagonist, and others. As per the route of administration, the market is segmented as oral anticoagulant and injectable anticoagulant. Application market-wise, it is classified as atrial fibrillation & heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and others.

According to region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By drug class

NOACs
Eliquis
Bevyxxa
Xarelto
Savaysa & lixiana
Pradaxa
Heparin & LMWH
Vitamin K antagonist
Others

By route of administration

Oral anticoagulant
Injectable anticoagulant

By application

Atrial fibrillation & heart attack
Stroke
Deep vein thrombosis (DVT)
Pulmonary embolism (PE)
Others

By region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Aspen Holdings
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo Company, Limited
GlaxoSmithKline plc.
Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
Pfizer, Inc.
Portola Pharmaceuticals, Inc.
Sanofi S.A.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request).

Armetheon, Inc.
Astrazeneca
Celgene Corporation

【レポートの目次】

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top player positioning

3.3. Market Dynamics

3.3.1. Drivers

3.3.1.1. Increase in prevalence of atrial fibrillation, venous thromboembolism and stroke
3.3.1.2. Rise in number of geriatric population
3.3.1.3. Increase in prevalence of obesity
3.3.1.4. Surge in healthcare expenditures worldwide

3.3.2. Restraints

3.3.2.1. High price of NOACs
3.3.2.2. Poor demand in under developed countries

3.3.3. Opportunity

3.3.3.1. Increase in demand for NOACs
3.3.3.2. Growth opportunities in emerging markets

3.3.4. Impact Analyses

CHAPTER 4: ANTICOAGULANTS MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. NOACs

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by type

4.2.2.1. Eliquis market size and forecast
4.2.2.2. Bevyxxa market size and forecast
4.2.2.3. Xarelto market size and forecast
4.2.2.4. Savaysa & Lixiana market size and forecast
4.2.2.5. Pradaxa market size and forecast

4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country

4.3. Heparins & LMWH

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Vitamin K Antagonists

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Other Anticoagulant Drugs

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

CHAPTER 5: ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Oral Anticoagulants

5.2.1. Market size and forecast
5.2.2. Market analysis, by country

5.3. Injectable Anticoagulants

5.3.1. Market size and forecast
5.3.2. Market analysis, by country

CHAPTER 6: ANTICOAGULANTS MARKET, BY APPLICATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Atrial Fibrillation & Heart Attack

6.2.1. Market size and forecast
6.2.2. Market analysis, by country

6.3. Stroke

6.3.1. Market size and forecast
6.3.2. Market analysis, by country

6.4. Deep Vein Thrombosis (DVT)

6.4.1. Market size and forecast
6.4.2. Market analysis, by country

6.5. Pulmonary Embolism (PE)

6.5.1. Market size and forecast
6.5.2. Market analysis, by country

6.6. Others

6.6.1. Market size and forecast
6.6.2. Market analysis, by country

CHAPTER 7: ANTICOAGULANTS MARKET BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country

7.2.2.1. U.S.

7.2.2.1.1. U.S. anticoagulants market, by drug class
7.2.2.1.2. U.S. anticoagulants market, by route of administration
7.2.2.1.3. U.S. anticoagulants market, by application

7.2.2.2. Canada

7.2.2.2.1. Canada anticoagulants market, by drug class
7.2.2.2.2. Canada anticoagulants market, by route of administration
7.2.2.2.3. Canada anticoagulants market, by application

7.2.2.3. Mexico

7.2.2.3.1. Mexico anticoagulants market, by drug class
7.2.2.3.2. Mexico anticoagulants market, by route of administration
7.2.2.3.3. Mexico anticoagulants market, by application

7.2.3. North America anticoagulants market, by drug class
7.2.4. North America anticoagulants market, by route of administration
7.2.5. North America anticoagulants market, by application

7.3. Europe

7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country

7.3.2.1. Germany

7.3.2.1.1. Germany anticoagulants market, by drug class
7.3.2.1.2. Germany anticoagulants market, by route of administration
7.3.2.1.3. Germany anticoagulants market, by application

7.3.2.2. France

7.3.2.2.1. France anticoagulants market, by drug class
7.3.2.2.2. France anticoagulants market, by route of administration
7.3.2.2.3. France anticoagulants market, by application

7.3.2.3. UK

7.3.2.3.1. UK anticoagulants market, by drug class
7.3.2.3.2. UK anticoagulants market, by route of administration
7.3.2.3.3. UK anticoagulants market, by application

7.3.2.4. Italy

7.3.2.4.1. Italy anticoagulants market, by drug class
7.3.2.4.2. Italy anticoagulants market, by route of administration
7.3.2.4.3. Italy anticoagulants market, by application

7.3.2.5. Spain

7.3.2.5.1. Spain anticoagulants market, by drug class
7.3.2.5.2. Spain anticoagulants market, by route of administration
7.3.2.5.3. Spain anticoagulants market, by application

7.3.2.6. Rest of Europe

7.3.2.6.1. Rest of Europe anticoagulants market, by drug class
7.3.2.6.2. Rest of Europe anticoagulants market, by route of administration
7.3.2.6.3. Rest of Europe anticoagulants market, by application

7.3.3. Europe anticoagulants market, by drug class
7.3.4. Europe anticoagulants market, by route of administration
7.3.5. Europe anticoagulants market, by application

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country

7.4.2.1. Japan

7.4.2.1.1. Japan anticoagulants market, by drug class
7.4.2.1.2. Japan anticoagulants market, by route of administration
7.4.2.1.3. Japan anticoagulants market, by application

7.4.2.2. China

7.4.2.2.1. China anticoagulants market, by drug class
7.4.2.2.2. China anticoagulants market, by route of administration
7.4.2.2.3. China anticoagulants market, by application

7.4.2.3. Australia

7.4.2.3.1. Australia anticoagulants market, by drug class
7.4.2.3.2. Australia anticoagulants market, by route of administration
7.4.2.3.3. Australia anticoagulants market, by application

7.4.2.4. India

7.4.2.4.1. India anticoagulants market, by drug class
7.4.2.4.2. India anticoagulants market, by route of administration
7.4.2.4.3. India anticoagulants market, by application

7.4.2.5. South Korea

7.4.2.5.1. South Korea anticoagulants market, by drug class
7.4.2.5.2. South Korea anticoagulants market, by route of administration
7.4.2.5.3. South Korea anticoagulants market, by application

7.4.2.6. Rest of Asia-Pacific

7.4.2.6.1. Rest of Asia-Pacific anticoagulants market, by drug class
7.4.2.6.2. Rest of Asia-Pacific anticoagulants market, by route of administration
7.4.2.6.3. Rest of Asia-Pacific anticoagulants market, by application

7.4.3. Asia-Pacific anticoagulants market, by drug class
7.4.4. Asia-Pacific anticoagulants market, by route of administration
7.4.5. Asia-Pacific anticoagulants market, by application

7.5. LAMEA

7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country

7.5.2.1. Brazil

7.5.2.1.1. Brazil anticoagulants market, by drug class
7.5.2.1.2. Brazil anticoagulants market, by route of administration
7.5.2.1.3. Brazil anticoagulants market, by application

7.5.2.2. Saudi Arabia

7.5.2.2.1. Saudi Arabia anticoagulants market, by drug class
7.5.2.2.2. Saudi Arabia anticoagulants market, by route of administration
7.5.2.2.3. Saudi Arabia anticoagulants market, by application

7.5.2.3. South Africa

7.5.2.3.1. South Africa anticoagulants market, by drug class
7.5.2.3.2. South Africa anticoagulants market, by route of administration
7.5.2.3.3. South Africa anticoagulants market, by application

7.5.2.4. Rest of LAMEA

7.5.2.4.1. Rest of LAMEA anticoagulants market, by drug class
7.5.2.4.2. Rest of LAMEA anticoagulants market, by route of administration
7.5.2.4.3. Rest of LAMEA anticoagulants market, by application

7.5.3. LAMEA anticoagulants market, by drug class
7.5.4. LAMEA anticoagulants market, by route of administration
7.5.5. LAMEA anticoagulants market, by application

CHAPTER 8: COMPANY PROFILES

8.1. Aspen Holdings

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product Portfolio
8.1.5. Business performance

8.2. Bayer AG

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product Portfolio
8.2.5. Business performance

8.3. Boehringer Ingelheim Pharma GmbH & Co. KG

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product Portfolio
8.3.5. Business performance

8.4. Bristol-Myers Squibb Company

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product Portfolio
8.4.5. Business performance

8.5. Daiichi Sankyo Co., Ltd.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Product Portfolio
8.5.4. Business performance

8.6. GlaxoSmithKline plc.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product Portfolio
8.6.5. Business performance

8.7. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance

8.8. Pfizer Inc.

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance

8.9. Portola Pharmaceuticals, Inc.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product Portfolio
8.9.4. Key strategic moves and developments

8.10. Sanofi

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. Business performance

TABLE 01. GLOBAL ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 02. NOAC MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 03. NOAC MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 04. HEPARINS & LMWH MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 05. VITAMIN K ANTAGONISTS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 06. OTHER ANTICOAGULANT DRUGS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 07. GLOBAL ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 08. ORAL ANTICOAGULANTS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 09. INJECTABLE ANTICOAGULANTS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 10. GLOBAL ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 11. ANTICOAGULANTS MARKET FOR ATRIAL FIBRILLATION & HEART ATTACK, BY REGION, 2017-2025 ($MILLION)
TABLE 12. ANTICOAGULANTS MARKET FOR STROKE, BY REGION, 2017-2025 ($MILLION)
TABLE 13. ANTICOAGULANTS MARKET FOR DEEP VEIN THROMBOSIS (DVT), BY REGION, 2017-2025 ($MILLION)
TABLE 14. ANTICOAGULANTS MARKET FOR PULMONARY EMBOLISM (PE), BY REGION, 2017-2025 ($MILLION)
TABLE 15. ANTICOAGULANTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2017-2025 ($MILLION)
TABLE 16. ANTICOAGULANTS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 17. NORTH AMERICA ANTICOAGULANTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 18. U.S. ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 19. U.S. ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 20. U.S. ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 21. CANADA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 22. CANADA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 23. CANADA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 24. MEXICO ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 25. MEXICO ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 26. MEXICO ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 27. NORTH AMERICA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 28. NORTH AMERICA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 29. NORTH AMERICA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 30. EUROPE ANTICOAGULANTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 31. GERMANY ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 32. GERMANY ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 33. GERMANY ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 34. FRANCE ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 35. FRANCE ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 36. FRANCE ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 37. UK ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 38. UK ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 39. UK ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 40. ITALY ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 41. ITALY ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 42. ITALY ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 43. SPAIN ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 44. SPAIN ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 45. SPAIN ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 46. REST OF EUROPE ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 47. REST OF EUROPE ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 48. REST OF EUROPE ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 49. EUROPE ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 50. EUROPE ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 51. EUROPE ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 52. ASIA- PACIFIC ANTICOAGULANTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 53. JAPAN ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 54. JAPAN ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 55. JAPAN ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 56. CHINA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 57. CHINA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 58. CHINA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 59. AUSTRALIA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 60. AUSTRALIA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 61. AUSTRALIA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 62. INDIA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 63. INDIA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 64. INDIA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 65. SOUTH KOREA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 66. SOUTH KOREA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 67. SOUTH KOREA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 71. ASIA-PACIFIC ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 72. ASIA-PACIFIC ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 73. ASIA-PACIFIC ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 74. LAMEA ANTICOAGULANTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 75. BRAZIL ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 76. BRAZIL ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 77. BRAZIL ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 78. SAUDI ARABIA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 79. SAUDI ARABIA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 80. SAUDI ARABIA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 81. SOUTH AFRICA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 82. SOUTH AFRICA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 83. SOUTH AFRICA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 84. REST OF LAMEA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 85. REST OF LAMEA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 86. REST OF LAMEA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 87. LAMEA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 88. LAMEA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 89. LAMEA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 90. ASPEN: COMPANY SNAPSHOT
TABLE 91. ASPEN: OPERATING SEGMENTS
TABLE 92. ASPEN: PRODUCT PORTFOLIO
TABLE 93. BAYER: COMPANY SNAPSHOT
TABLE 94. BAYER: OPERATING SEGMENTS
TABLE 95. BAYER: PRODUCT PORTFOLIO
TABLE 96. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 97. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 98. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 99. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 100. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 101. DAIICHI SANKYO: COMPANY SNAPSHOT
TABLE 102. DAIICHI SANKYO: PRODUCT PORTFOLIO
TABLE 103. GSK: COMPANY SNAPSHOT
TABLE 104. GSK: OPERATING SEGMENTS
TABLE 105. GSK: PRODUCT PORTFOLIO
TABLE 106. J&J: COMPANY SNAPSHOT
TABLE 107. J&J: OPERATING SEGMENTS
TABLE 108. J&J: PRODUCT PORTFOLIO
TABLE 109. PFIZER: COMPANY SNAPSHOT
TABLE 110. PFIZER: OPERATING SEGMENTS
TABLE 111. PFIZER: PRODUCT PORTFOLIO
TABLE 112. PORTOLA: COMPANY SNAPSHOT
TABLE 113. PORTOLA: PRODUCT PORTFOLIO
TABLE 114. SANOFI: COMPANY SNAPSHOT
TABLE 115. SANOFI: OPERATING SEGMENTS
TABLE 116. SANOFI: PRODUCT PORTFOLIO

FIGURE 01. ANTICOAGULANTS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS IN THE GLOBAL ANTICOAGULANTS MARKET
FIGURE 03. TOP PLAYER POSITIONING, 2017
FIGURE 04. WORLD POPULATION AGED 65 AND OVER (%)
FIGURE 05. IMPACT ANALYSES
FIGURE 06. ELIQUIS MARKET REVENUE, 2017-2025 ($MILLION)
FIGURE 07. BEVYXXA MARKET REVENUE, 2017-2025 ($MILLION)
FIGURE 08. XARELTO MARKET REVENUE, 2017-2025 ($MILLION)
FIGURE 09. SAVAYSA & & LIXIANA MARKET REVENUE, 2017-2025 ($MILLION)
FIGURE 10. PRADAXA MARKET REVENUE, 2017-2025 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF NOAC MARKET, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF HEPARINS & LMWH MARKET, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF VITAMIN K ANTAGONISTS MARKET, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF OTHER ANTICOAGULANT DRUGS MARKET, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF ORAL ANTICOAGULANTS, BY COUNTRY, 2017 & 2025 (%)
FIGURE 16. COMPARATIVE ANALYSIS OF INJECTABLE ANTICOAGULANTS MARKET, BY COUNTRY, 2017 & 2025 (%)
FIGURE 17. COMPARATIVE ANALYSIS OF ANTICOAGULANTS MARKET FOR ATRIAL FIBRILLATION & HEART ATTACK, BY COUNTRY, 2017 & 2025 (%)
FIGURE 18. COMPARATIVE ANALYSIS OF ANTICOAGULANTS MARKET FOR STROKE, BY COUNTRY, 2017 & 2025 (%)
FIGURE 19. COMPARATIVE ANALYSIS OF ANTICOAGULANTS MARKET FOR DEEP VEIN THROMBOSIS (DVT), BY COUNTRY, 2017 & 2025 (%)
FIGURE 20. COMPARATIVE ANALYSIS OF ANTICOAGULANTS MARKET FOR PULMONARY EMBOLISM (PE), BY COUNTRY, 2017 & 2025 (%)
FIGURE 21. COMPARATIVE ANALYSIS OF ANTICOAGULANTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017 & 2025 (%)
FIGURE 22. ASPEN: REVENUES, 2015-2017 ($MILLION)
FIGURE 23. ASPEN: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 24. ASPEN: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 25. BAYER: REVENUE, 2015-2017 ($MILLION)
FIGURE 26. BAYER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 27. BOEHRINGER INGELHEIM: NET SALES, 2015-2017 ($MILLION)
FIGURE 28. BOEHRINGER INGELHEIM: NET SALES BY BUSINESS, 2017 (%)
FIGURE 29. BOEHRINGER INGELHEIM: NET SALES BY REGION, 2017 (%)
FIGURE 30. REVENUE, 2015-2017 ($MILLION)
FIGURE 31. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 32. DAIICHI SANKYO: NET SALES, 2015-2017 ($MILLION)
FIGURE 33. GSK: REVENUE, 2015-2017 ($MILLION)
FIGURE 34. GSK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 35. GSK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 36. J&J: REVENUE, 2015-2017 ($MILLION)
FIGURE 37. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 38. J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 39. PFIZER: REVENUE, 2015-2017 ($MILLION)
FIGURE 40. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 42. SANOFI: NET SALES, 2015-2017 ($MILLION)
FIGURE 43. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 44. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 抗凝固薬の世界市場2018-2025(Anticoagulants Market by Drug Class (NOACs, Heparin & LMWH, Vitamin K Antagonist, and Others), Route of Administration (Oral Anticoagulant and Injectable Anticoagulant), and Application (Atrial Fibrillation & Heart Attack, Stroke, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025 )]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆